Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.67 |
| ▸ | KCNB1 | Q14721 | 9/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15532866 | 0.90 | NTRK1 (0.70) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15533241 | 0.89 | NTRK1 (0.69) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15533697 | 0.88 | NTRK1 (0.60) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15533136 | 0.88 | NTRK1 (0.69) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15534347 | 0.87 | NTRK1 (0.80) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL16714219 | 0.86 | NTRK1 (0.60) | NTRK1KCNB1CTSD | |
| SCHEMBL15533086 | 0.85 | NTRK1 (0.74) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15533564 | 0.85 | NTRK1 (0.72) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15546824 | 0.84 | NTRK1 (0.76) | NTRK1KCNB1KCNA5KCNH2ROCK2 | |
| SCHEMBL15534174 | 0.84 | NTRK1 (0.71) | NTRK1KCNB1KCNA5KCNH2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | claimed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | claimed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | NGF, NGFR, NTRK1 | NTRK1 3/4885KCNB1 1686/4885KCNA5 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.